Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients

Phase 4

Completed

Brief Summary: This research study proposes to conduct an open label, feasibility study administering prophylactic oral haldol to patients undergoing a hematopoietic stem cell transplant (HSCT).

The study will address the following research aims: 1) To demonstrate the feasibility of enrolling HSCT patients in a prophylactic medication trial, 2) To determine the tolerability of oral haldol in HSCT patients and 2) To compare rates of delirium in HSCT patients who receive prophylactic haldol with an untreated historical control group.

Detailed Description: This is an open label, safety \& feasibility, clinical drug trial. We will use historical controls from previous research with bone marrow transplant patients and delirium incidence at University of Iowa Hospitals and Clinics (UIHC) to evaluate the efficacy of prophylactic Haldol in the prevention of delirium. This study will recruit adult cancer patients undergoing hematopoietic stem cell transplant (HSCT) at UIHC.

Recruitment & Eligibility

Inclusion Criteria

The participant must undergo an autologous or allogeneic bone marrow or stem cell transplant
The participant is 18 years of age or older
The participant provides written consent

Exclusion Criteria

The participant has a QTc of >450 msec at the time of enrollment
The participant used any antipsychotic medications within the last 30 days
The participant has any significant allergies or past intolerance to Haloperidol
The participant has a history of major neurological, metabolic, psychiatric, or cardiovascular disease, cerebrovascular event, or substance abuse
The participant has a history of mental retardation or learning disability that, at the discretion of the investigator, could affect their ability to complete study assessments.

Arm && Interventions

Group	Intervention	Description
Oral Haldol in patients undergoing HSCT	Haldol	Prior to stem cell transplant participants will receive 5mg of liquid or pill form, oral Haldol. Every other day visits will take place following the first administration of the study drug until 14 days after the transplant.

Primary Outcome Measures

Name	Time	Method
Side Effects and Tolerability of Haldol in Patients With Undergoing Hematopoietic Stem Cell Transplant	Daily, up to 14 days following transplant	Categorize and quantify adverse events from start of drug (day 1) to end of study drug per (CTCAE) version 4.0

Secondary Outcome Measures